Company
.:[TICKER]
The MMIH Group is an enterprise headquartered in Singapore with minerals exploration and mining interests in the Philippines and other geographies in Southeast Asia. The group has a diverse and talented board of directors and industry experts.
170 stories · page 2 of 9
The successful completion of the trial will support EMD-RX5’s registration with the Therapeutic Goods Administration (TGA) as a schedule 3, over-the-counter treatment (OTC) for the symptoms of psychological distress, for which there is curr
“Fibrotic diseases represent a major group of unmet medical needs and our early screening results indicate some analogues may have potent antifibrotic activity,” said managing director Dr Michael Winlo.
Striate+™ is a market-leading resorbable collagen membrane used in guided bone and tissue regeneration procedures.
“Emyria’s preclinical drug discovery program, inspired by MDMA, is making great progress. We are strengthening Emyria’s intellectual property portfolio and potential slate of proprietary drug candidates targeting major unmet needs,” MD Dr M
“The agreements with BioHorizons represent a significant milestone for Orthocell and provide further external commercial and technical validation of the CelGro™ collagen scaffold platform, from which the Striate+ dental products were develo
The company is well-positioned to establish its CelGro® product as the best-in-class membrane for bone and soft tissue repair and to realise multiple commercial partnering opportunities.
The company’s current drug registration programs span its EMD-003 CBD medicine targeting mental health, EMD-004 for IBS and EMDMA-001 MDMA psychedelic-assisted therapy program targeting sufferers of treatment-resistant PTSD.
“The treatment I received to repair my nerve damage has been completely life-altering. I had lost full function of my hand, making the simplest of tasks impossible – from tying my own shoelaces to changing my baby’s nappy,” says trial parti
MD Paul Anderson says the receipt of the R&D tax incentive refund will further strengthen the company's capital position and support the scale up of key assets, delivering significant shareholder value.
“Emyria's clinical development expertise, funding and international networks have taken our MDMA analogue research to the next level,” says UWA Professor Matt Piggott.
“These pharmacokinetic data show Emyria has rapidly developed a unique, ultra-pure cannabidiol capsule with excellent safety and tolerability and highly favourable drug delivery and absorption characteristics," says MD Dr Michael Winlo.
Last year, Emyria recently secured exclusive rights to a library of more than 100 novel MDMA analogues (and counting) from the University of Western Australia, creating a unique drug-discovery pipeline.
State governments passed legislation which permits medicinal cannabis to be prescribed to certain patient groups or under certain circumstances and thus it is medical use that most Australian listed cannabis companies are focusing on, as th
Emyria believes EMD-RX5 has the potential to address multiple clinical indications as a registered medicine where low doses of CBD appear to be effective.
EMD-RX5 is initially designed as an over-the-counter (Schedule 3) treatment that treats psychological distress, which affects 15% of adults, and for which there is currently no over-the-counter treatments.
The asset, EMD-RX5, is Emyria’s first solid, oral dose form of ultra-pure CBD. It will target psychological distress, for which there is currently no over-the-counter remedy.
“Remplir™ is the first of its kind biological scaffold designed by an Australian team of researchers to mimic the outer layer of the peripheral nerve and facilitate high-quality nerve repair. Remplir™ is the only Australian manufactured med
“Now, with EMD-RX7, we have a convenient dose form that we believe can deliver higher CBD exposures more efficiently allowing us to target a range of prescription-only indications - in other words, help the broad range of major unmet needs
Woodside has weighed in with chief executive Meg O'Neill saying, "We've seen gas prices that have spiked at levels that are even more unprecedented than the oil prices, so the Asian price marker hit $US82 per million British thermal units.
“Emyria’s first registration program is aimed at developing an over-the-counter, Schedule 3 treatment targeting the symptoms of psychological distress – a growing global mental health concern affecting about 15% of all adults in Australia a
